Home > Dermatology > PsoBarrier EU: Large survey evaluating quality of care in Europe

PsoBarrier EU: Large survey evaluating quality of care in Europe

Presented By
Dr Anna Langenbruch, UniversitÀtsklinikum Hamburg-Eppendorf, Germany
Conference
WPPAC 2021
Trial
PsoBarrier EU
The PsoBarrier EU study was a European effort investigating over 1,300 patients with psoriasis. This study was awarded the best educational poster for furthering our understanding of how psoriasis and possibly psoriatic arthritis can be effectively treated with available measures [1]. This is one of the first international studies on barriers in psoriasis care. A previous nationwide study demonstrated that psoriasis care continuously improved in Germany between 2004 and 2017, although some deficits persist. Few comparable studies in European countries were available. The PsoBarrier EU analysed the quality of healthcare in 4 European countries: Spain, Germany, Denmark, and Poland [2,3]. Patients were asked identical questions on a broad spectrum of issues, mainly patient-reported outcomes, but also questions about the severity of the disease. Dr Anna Langenbruch (UniversitÀtsklinikum Hamburg-Eppendorf, Germany) shared the results of the study concern...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on